FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: AstraZeneca to Invest $405 Million in UK Sites

By

AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported Wednesday.

The investment will fund expansion at AstraZeneca's Cambridge biomedical campus and boost manufacturing and research capabilities at its Macclesfield site, according to the report.

In a statement to, AstraZeneca CEO Pascal Soriot praised the UK government for its efforts to "improve access for patients, including four new approvals since the beginning of the year across the UK." He said the company is looking forward to "further enhancing the access and the reimbursement environment and build a strong life sciences sector."

Soriot said AstraZeneca is "investing a total of 300 million pounds in the UK, which includes investment in our Macclesfield site, including a lab of the future that will use digital and data tools to advance drug development."

Shares of AstraZeneca were down 2.3% in US trading on Wednesday.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $183.67, Change: $-3.07, Percent Change: -1.64%

Related Articles

Wire

Brown-Forman, Pernod Ricard End Talks on Potential Combination

Brown-Forman (BF.A) and Pernod Ricard ended discussions over a potential business combination after failing to reach mutually agreeable terms."We intend to create long-term value for all stakeholders by focusing on our strategic and operational priorities," Brown-Forman said Tuesday in a statement. "This includes unlocking future growth by expanding our geographic footprint, continuing to build brands that resonate with consumers, and enhancing operational efficiency."In late March, the companies confirmed they were in talks, noting "there could be no assurance that any such agreement would be reached."Brown-Forman shares fell 2.9% in after-hours trading.

$BF.A$BF.B
Wire

Update: Visa Fiscal Q2 Adjusted Earnings, Revenue Rise

(Updates with share repurchase and dividend information in the last two paragraphs.)Visa (V) reported fiscal Q2 adjusted earnings late Tuesday of $3.31 per diluted share, up from $2.76 a year earlier.Analysts polled by FactSet expected $3.10.Revenue for the three months ended March 31 was $11.23 billion, up from $9.59 billion a year earlier.Analysts polled by FactSet expected $10.75 billion.In April, the company's board authorized a new $20 billion multi-year share repurchase program, it said.Visa also maintained its quarterly dividend at $0.67 per share, payable June 1 to holders on record as of May 12.

$V
Wire

BXP Q1 FFO Falls, Revenue Rises; Shares Drop After Hours

BXP Inc (BXP) reported Q1 funds from operations late Tuesday of $1.59 per diluted share, down from $1.64 a year earlier.Analysts surveyed by FactSet expected $1.58.Revenue in the three months ended March 31 rose to $872.1 million from $865.2 million a year earlier.Analysts polled by FactSet expected $843.1 million.The company expects FFO of $1.69 to $1.71 a share in Q2 and $6.90 to $7.04 a share in the full year, compared with the prior forecast of $6.88 to $7.04.Analysts surveyed by FactSet expect $1.72 in Q2 and $6.95 in the full year.BXP shares fell 4.6% in after-hours trading.

$BXP